P/E ratio for Ironwood Pharmaceuticals (IRWD)
P/E ratio as of April 2024 (TTM): -1.38
According to Ironwood Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.37521. At the end of 2022 the company had a P/E ratio of 10.9.
P/E ratio history for Ironwood Pharmaceuticals from 2010 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 10.9 | 203.87% |
| 2021 | 3.58 | -78.96% |
| 2020 | 17.0 | -82.12% |
| 2019 | 95.1 | -2127.06% |
| 2018 | -4.69 | -70.11% |
| 2017 | -15.7 | -31.37% |
| 2016 | -22.9 | 135.58% |
| 2015 | -9.71 | 5.16% |
| 2014 | -9.23 | 125.94% |
| 2013 | -4.09 | -69.62% |
| 2012 | -13.4 | -11.46% |
| 2011 | -15.2 | 8.64% |
| 2010 | -14.0 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 AstraZeneca AZN | 35.9 | -2,708.26% | 🇬🇧 UK |
 Nektar Therapeutics
NKTR | -0.8466 | -38.44% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.